Atara Biotherapeutics, Inc.

Total Valuation

Atara Biotherapeutics, Inc. carries a market capitalization of 76.95M, placing it among publicly traded companies globally. Its enterprise value stands at 108.41M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Atara Biotherapeutics, Inc. currently has 9.44M shares outstanding.

Valuation Ratios

Atara Biotherapeutics, Inc. trades at a trailing price-to-earnings ratio of 12.28. The price-to-sales ratio is 26.37, and the price-to-book ratio stands at -2.93.

Enterprise Valuation

The EV/Sales ratio of 17.50 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 7.81 provides insight into valuation relative to core operating earnings.

Financial Position

Atara Biotherapeutics, Inc. maintains a current ratio of 1.98, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -26.70, indicating conservative leverage, while an interest coverage ratio of -4.99 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Atara Biotherapeutics, Inc.'s stock has declined approximately -38.25018% over the past 52 weeks. The 50-day moving average sits at 8.94, while the 200-day moving average is 8.54.

Income Statement

Over the trailing twelve months, Atara Biotherapeutics, Inc. generated 6.19M in revenue and converted that into -16.69M in net income, yielding earnings per share of -1.17. EBITDA reached -14.10M, while operating income came in at -14.23M.

Balance Sheet

Atara Biotherapeutics, Inc. holds 9.87M in cash and equivalents against 9.88M in total debt, resulting in a net debt position of -3.22M. Total book value stands at -37.00M, with working capital of 6.68M providing operational flexibility.

Cash Flow

Atara Biotherapeutics, Inc. produced -21.89M in operating cash flow over the past twelve months.

Margins

Atara Biotherapeutics, Inc. operates with a gross margin of 91.38, reflecting its pricing power and cost economics. The operating margin of -229.67 and net profit margin of -269.42 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Atara Biotherapeutics, Inc.'s most recent stock split took place on June 20, 2024 with a 25:1 split ratio.

Scores

Atara Biotherapeutics, Inc. posts an Altman Z-Score of -135.67, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.